Project Grant R21AG102518
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $533,500 to the Buck Institute for Research on Aging on July 15, 2026, under the Aging Research program (CFDA 93.866). The award funds examination of the role of autonomic innervation in muscle stem cell aging. The research investigates the functional link between autonomic nervous system neurons and muscle stem cells using Drosophila melanogaster as a model organism. The project will refine...
- The National Institute on Aging awarded New York University $466,125 under the Aging Research program (CFDA 93.866) on January 15, 2026, to develop innovative magnetic resonance imaging analysis tools for identifying microstructural biomarkers of skeletal muscle health across the lifespan. The project, titled "(Micro)structural Biomarkers of Skeletal Muscle Health Across the Lifespan," addresses sarcopenia—a leading cause of disability and mortality in aging populations—by creating...
- This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $287,218.16 in funding to the University of Maryland, Baltimore from August 1, 2021 through March 27, 2022. The award supports research aimed at better understanding the impact of aging on muscle excitability and action potential conduction velocity. Specifically, the recipient will use electrophysiology techniques and optical imaging to examine...
- The National Institute on Aging awarded $648,930 to the Regents of the University of California, doing business as University of California, Berkeley, on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop human stem cell-based microphysiological systems for aging research. The recipient will create a novel human aging-on-a-chip platform integrating fat and liver tissues derived from human induced pluripotent stem cells (hiPSCs) and microfluidics using serum from young...
- This $485,375 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research at the University of Washington to investigate genomic alterations in skeletal muscle associated with aging. The key objectives are to: Explore if alternative splicing of mRNA results in quantitative differential isoform changes associated with aging, potentially leading to increased expression of non-functional proteins relevant for healthy muscle function. The researchers...
- The National Institute on Aging awarded The Leland Stanford Junior University $658,147 for Project Grant R01AG096626 on September 1, 2026, under the Aging Research program (CFDA 93.866). The award funds research into mechanisms of skeletal muscle maintenance relevant to Alzheimer's disease and Alzheimer's disease-related dementia. The research examines how mitochondrial dysfunction, particularly reverse electron transport along mitochondrial complex I, contributes to NAD+ depletion during aging....
- The National Institute on Aging awarded the University of Washington $485,375 under the Aging Research program (CFDA 93.866) on September 1, 2026 for Project Grant R21AG102427. The award funds development and expansion of naturally aged three-dimensional engineered muscle tissue (3D-EMT) models to test metabolic and contractile function in vitro as a mechanistic platform for studying sarcopenia. The research examines the contribution of extracellular factors to aged 3D-EMT function and...
- The National Institute on Aging awarded Drexel University $420,554 under Aging Research (CFDA 93.866) on September 1, 2026, to establish an integrated system for studying senescence and aging in the central nervous system. The award funds two research aims: characterization of the molecular and functional consequences of senescence in astrocyte and neuronal cultures, and evaluation of senescence impact in a multicellular context using hiPSC-derived vascularized cortical organoids. Single-cell...
- This $485,375 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support the development and evaluation of a 3D engineered muscle tissue model to study the metabolic response to muscle contraction in the context of aging. The University of Washington, a prominent research institution, will lead this 2-year project to: 1) examine the mitochondrial mechanisms underlying the decreased metabolic response to muscle contraction in aged human 3D engineered...
- The National Institute on Aging, within the Department of Health and Human Services, awarded $434,856 to the University of Nebraska Board of Regents on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of microRNAs in sarcopenia through a novel muscle-specific mouse model. The recipient will test the hypothesis that microRNA dysregulation contributes to age-related muscle loss by pursuing two specific aims: blocking microRNA-mediated gene repression to...
The National Institute on Aging, part of the Department of Health and Human Services, awarded The Johns Hopkins University $427,625 for Project Grant R21AG102518 on September 1, 2026, under the Aging Research program (CFDA 93.866). The recipient will develop a human three-dimensional neuromuscular microphysiological system to model skeletal muscle aging ex vivo. The platform integrates primary human muscle stem cells from young (20–30 years) and aged (60–75 years) donors, induced pluripotent stem cell-derived motor neurons, and fibrogenic progenitors within a compartmentalized microfluidic chip that recapitulates the human motor unit. The system incorporates optogenetic control of motor neuron activity via channelrhodopsin-2 and real-time contractility measurements using embedded magnetic sensors in a modular, scalable format suitable for high-throughput drug screening. Multi-omic endpoint analyses (transcriptomic and proteomic) will identify molecular aging signatures and mechanistic drivers of neuromuscular decline. The work targets the deterioration of the neuromuscular junction due to denervation, impaired reinnervation driven by mitochondrial dysfunction, and oxidative stress, processes poorly captured by existing rodent models. Performance occurs in Baltimore, Maryland. The project period runs September 1, 2026, through August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $427.6k | 9/1/26 |